Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis

NCT02693093 is registered in ClinicalTrials.gov with Kangen Pharmaceuticals, Inc as lead sponsor.

NCT NCT02693093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02693093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis
Lead sponsor
Kangen Pharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
February 24, 2016
Completion date
December 30, 2021
Enrollment
264 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pancreatitis